Form D · Pharmaceuticals
New Haven Pharmaceuticals, Inc.
North Haven, CT · CIK 0001558788
Offering snapshot reported Aug 17, 2016 · SEC filing
- Reported sold
- $602K Offering amount: $1.3M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 1, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 17, 2016 | Initial | $602,222 | No comparison | 3 | SEC filing |
| Oct 23, 2014 | Initial | $11,786,611 | No comparison | 9 | SEC filing |
| Oct 2, 2012 | Initial | $6,490,773 | No comparison | 17 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-269056
Source: Form D, filed Aug 17, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Larry Dillaha | Director |
| Christopher Ecklund | Director |
| Patrick Fourteau | Director, Executive |
| Scott Kozak | Promoter |
| Nancy Motola | Executive |
| Harry H. Penner, Jr. | Director, Executive |
| William Sessa | Director |
| Theodore Stanley | Director |
| Rob Sterling | Promoter |
| Daniel Wagner | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
116 Washington Avenue 4 Th Floor
North Haven, CT, 06473
North Haven, CT, 06473